A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 724
- Registration Number
- NCT06664619
Mass Balance Clinical Trial With TEV-56286
- Conditions
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06627231
- Locations
- 🇳🇱
Teva Investigational Site 38189, Groningen, Netherlands
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06625177
- Locations
- 🇺🇸
Teva Investigational Site 12046, Pasadena, California, United States
🇺🇸Teva Investigational Site 12049, Miramar, Florida, United States
🇺🇸Teva Investigational Site 12047, Chicago, Illinois, United States
A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT06568237
- Locations
- 🇺🇸
Teva Investigational Site 15544, Boca Raton, Florida, United States
🇺🇸Teva Investigational Site 15543, Spokane, Washington, United States
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT06480552
- Locations
- 🇺🇸
Teva Investigational Site 12016, Chicago, Illinois, United States
🇺🇸Teva Investigational Site 12015, Detroit, Michigan, United States
🇺🇸Teva Investigational Site 12058, Pittsburgh, Pennsylvania, United States
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT06319170
- Locations
- 🇺🇸
Teva Investigational Site 15730, Los Alamitos, California, United States
🇺🇸Teva Investigational Site 15727, Hollywood, Florida, United States
🇺🇸Teva Investigational Site 15729, Atlanta, Georgia, United States
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT06315283
- Locations
- 🇬🇧
Teva Investigational Site 34310, Surrey, United Kingdom
🇺🇸Teva Investigational Site 15739, Los Alamitos, California, United States
🇺🇸Teva Investigational Site 15740, Torrance, California, United States
Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06290102
- Locations
- 🇺🇸
Teva Investigational Site 12010, Mobile, Alabama, United States
🇺🇸Teva Investigational Site 12003, Long Beach, California, United States
🇺🇸Teva Investigational Site 12007, Miami, Florida, United States
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06253546
- Locations
- 🇨🇳
Teva Investigational Site 88047, Guangzhou, China
🇨🇳Teva Investigational Site 88056, Xi'an Shi, China
🇨🇳Teva Investigational Site 88046, Shanghai, China
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 2196
- Registration Number
- NCT06052267
- Locations
- 🇺🇸
Teva Investigational Site 15610, Elizabeth City, North Carolina, United States
🇺🇸Teva Investigational Site 15651, High Point, North Carolina, United States
🇺🇸Teva Investigational Site 15631, Wilmington, North Carolina, United States